E149 - (CME) Shared Decision Making and Patient Education for Optimizing Treatment of Tardive Dyskinesia

55:06
 
Share
 

Manage episode 329708484 series 3353099
By Neuroscience Education Institute. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
In this episode, Dr. Andrew Cutler interviews Dr. Diana Perkins on best practices for shared decision making and patient education. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD02

Learning Objectives: After completing this educational activity, you should be better able to:

  • Educate patients and family members with mood disorders and schizophrenia about the symptoms of tardive dyskinesia
  • Address psychosocial and quality-of-life concerns related to tardive dyskinesia in patients with mood disorders and schizophrenia
  • Include patients, caregivers, and family members in shared decision-making when applicable to optimize patient outcomes before and during of treatment of tardive dyskinesia

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.

Credit Types. The following are being offered for this activity:

  • Nurse Practitioner (ANCC): contact hours
  • Pharmacy (ACPE): knowledge-based contact hours
  • Physician (ACCME): AMA PRA Category 1 Credits
  • Physician Assistant (AAPA): Category 1 CME credits
  • Psychology (APA): CE credits
  • Social Work (ASWB-ACE): ACE CE credits
  • Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva

Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva

Interviewee

Diana Perkins, MD, MPH

Professor, Department of Psychiatry; Medical Director, Outreach and Support Intervention Services; University of North Carolina School of Medicine, Chapel Hill, NC

Consultant/Advisor: Alkermes, Karuna

Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies, and strategies for understanding and reducing implicit bias can be found in this can be found in this linked handout.

Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

Released: May 27, 2022 CE credit expires: May 27, 2025

160 episodes